Evidence map›Paper›PMID 36931504›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023

Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit.

Olawale Akinbobola, Meredith A Ray, Carrie Fehnel, Andrea Saulsberry, Kourtney Dortch, Matthew Smeltzer, Nicholas R Faris, Raymond U Osarogiagbon

Abstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Olawale AkinbobolaThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee.
Meredith A RaySchool of Public Health, University of Memphis, Memphis, Tennessee.
Carrie FehnelThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee.
Andrea SaulsberryThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee.
Kourtney DortchThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee.
Matthew SmeltzerSchool of Public Health, University of Memphis, Memphis, Tennessee.
Nicholas R FarisThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee; Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.
Raymond U OsarogiagbonThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee; Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee. Electronic address: rosarogi@bmhcc.org.

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

introductionLung cancer surgery with a lymph node kit improves patient-level outcomes, but institution-level impact is unproven.

methodsUsing an institutional stepped-wedge implementation study design, we compared lung cancer resection quality between institutions in preimplementation and postimplementation phases of kit deployment and, within implementing institutions, resections without versus with the kit. Benchmarks included rates of nonexamination of lymph nodes, nonexamination of mediastinal lymph nodes, and attainment of American College of Surgeons Operative Standard 5.8. We report institution-level adjusted ORs (aORs) for attaining quality benchmarks.

resultsFrom 2009 to 2020, three preimplementing hospitals had 953 resections; 11 implementing hospitals had 4013 resections, 58% without and 42% with the kit. Quality was better in implementing institutions and with kit cases. Compared with preimplementing institutions, the aOR for nonexamination of lymph nodes was 0.62 (0.49-0.8, p = 0.002), nonexamination of mediastinal lymph nodes was 0.56 (0.47-0.68, p < 0.0001), and attainment of Operative Standard 5.8 was 7.3 (5.6-9.4, p < 0.0001); aORs for kit cases were 0.01 (0.001-0.06), 0.08 (0.06-0.11), and 11.6 (9.9-13.7), respectively (p < 0.0001 for all). Surgical quality was persistently poor in preimplementing institutions but sequentially improved in implementing institutions in parallel with kit adoption. In implementing institutions, resections with the kit had a uniformly high level of quality, whereas nonkit cases had a low level of quality, approximating that of preimplementing institutions. Within implementing institutions, 5-year overall survival was 61% versus 51% after surgery with versus without the kit (p < 0.001).

conclusionsSurgery with a lymph node specimen collection kit improved institution-level quality of curative-intent lung cancer resection.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansLymph Node ExcisionLymph NodesNeoplasm StagingPneumonectomyRetrospective StudiesSpecimen HandlingLung cancerLymph node collectionPatient outcomesQuality of surgery

Identifiers

PMID36931504
PMCPMC10505555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.